IDO1 and neoplasm: Consistent with the TCGA EOC data, syngeneic wild-type (WT) C57BL/6 mice challenged with IE9mp1-mIDO1 displayed earlier onset of tumor burden (Figure 1C) and a significant decrease in overall survival compared with tumors that lack IDO1 expression (Figure 1D).